BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

I would now like to turn the conference over to John Bluth. Please go ahead. Thank you very much. Good morning and welcome to Biochris second quarter 2025 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO John Stonehouse, President and Chief Commercial Officer Charlie Geyer, Chief R&D Officer Dr. Helen Thackeray, Chief Medical Officer Dr. Donald Fong, and our new Chief Financial Officer Barbara Gias. Following our remarks, we will answer your questions. Today's conference call will contain forward-looking statements, including those statements regarding future results on audited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. In addition, today's conference call includes non-GAAP financial measures. For reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings press release posted in the press releases section of our investor relations website at www.biocrist.com. I'd now like to turn the call over to John Stonehouse. Thanks, John. Q2 was another outstanding quarter of performance for Biocrist. For ...